Search

everythinglearnresearchcommunity

for

Search:↓

A product with Minoxidil, finasteride, and RU58841 may help with hair thinning, but effectiveness varies, especially in aggressive cases. More potent treatments might be necessary for severe androgenetic alopecia (AGA).

A 33-year-old experienced significant hair loss after a depressive episode and taking paroxetine, possibly due to telogen effluvium or androgenic alopecia. Suggestions included reducing alcohol, considering finasteride and minoxidil, and consulting a doctor about antidepressant side effects.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

A 25-year-old male experiencing hair loss suspects stress-related alopecia and is hesitant to use Minoxidil due to potential side effects. Another user suggests it might be androgenic alopecia and recommends starting finasteride.

An 18-year-old has been using 5% topical minoxidil for 2 months for hair loss, with a history of vitamin D deficiency and thyroid imbalance. Users suggest starting finasteride and blocking DHT for androgenetic alopecia (AGA).

The user has been using 1mg finasteride and 2.5mg oral minoxidil daily for 18 months without success in treating hair loss. They are frustrated with their diffuse androgenetic alopecia and unsure of what to do next.

The user noticed increased hair loss over the past three years and is seeking advice. A suggestion was made to consult a dermatologist or trichologist and consider blood tests, particularly for vitamin D levels, to address potential androgenetic alopecia (AGA).

Finasteride is being used by a 17-year-old concerned about its impact on height while still growing. The user has been balding since age 13 and was recently diagnosed with androgenetic alopecia.

The user is experiencing significant hair thinning on the front scalp while taking oral finasteride and minoxidil. They are unsure if it's androgenetic alopecia or related to seborrheic dermatitis.

The user is experiencing hair loss with symptoms of receding hairline, extreme shedding, and low density, possibly due to androgenic alopecia, diffuse thinning, retrograde alopecia, or telogen effluvium. They have used minoxidil and noticed changes in shedding patterns related to different water qualities and seborrheic dermatitis.

Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A 21-year-old is experiencing hair thinning and is using oral finasteride and topical minoxidil, considering adding oral minoxidil. They are unsure if the condition is androgenetic alopecia (AGA) or telogen effluvium (TE) and are advised to continue treatments and get a blood test.

The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

A 17-year-old is frustrated with hair thinning and receding temples, seeking advice after a dermatologist dismissed concerns. Suggestions include starting Minoxidil for regrowth and considering Finasteride if androgenetic alopecia is suspected.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

The user shared progress photos after using minoxidil 2.5mg and dutasteride 0.5mg daily for hair growth, starting in summer 2024. They reported no noticeable side effects and confirmed androgenetic alopecia in 2024.

A 24-year-old from the EU is experiencing hair thinning at the crown, possibly due to androgenetic alopecia. Suggested treatments include minoxidil and finasteride, which can be used in topical or oral forms.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

The conversation discusses using Minoxidil with Tretinoin and Fexofenadine for hair loss. Some users doubt its effectiveness, noting Fexofenadine's unproven results for androgenetic alopecia.

Aloe vera gel can help reduce scalp inflammation and "DHT itch" associated with hair loss, particularly in those with androgenic alopecia and seborrheic dermatitis. It's suggested to use aloe vera alongside treatments like finasteride and ketoconazole shampoo to manage symptoms and promote scalp health.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A user is concerned about hair thinning and is using minoxidil, considering finasteride, and planning blood tests to rule out deficiencies. They are advised to consult a dermatologist to confirm if androgenic alopecia is the cause before starting finasteride.